DSCAM-AS1 regulates the G1/S cell cycle transition and is an independent prognostic factor of poor survival in luminal breast cancer patients treated with endocrine therapy

被引：32
作者：
Sun, Wei [1 ,2 ,3 ]
Li, An-Qi [2 ,3 ,4 ]
Zhou, Ping [5 ]
Jiang, Yi-Zhou [1 ,2 ,3 ]
Jin, Xi [1 ,2 ,3 ]
Liu, Yi-Reng [1 ,2 ,3 ]
Guo, Ya-Jie [1 ,2 ,3 ]
Yang, Wen-Tao [2 ,3 ,4 ]
Shao, Zhi-Ming [1 ,2 ,3 ,6 ]
Xu, Xiao-En [1 ,2 ,3 ]
机构：
[1] Fudan Univ, Dept Breast Surg, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Fudan Univ, Canc Inst, Shanghai Canc Ctr, Shanghai, Peoples R China
[3] Fudan Univ, Dept Oncol, Shanghai Canc Ctr, Shanghai, Peoples R China
[4] Fudan Univ, Dept Pathol, Shanghai Canc Ctr, Shanghai, Peoples R China
[5] Third Hosp Nanchang, Dept Breast Surg, Nanchang, Jiangxi, Peoples R China
[6] Fudan Univ, Inst Biomed Sci, Shanghai, Peoples R China
来源：
CANCER MEDICINE | 2018年 / 7卷 / 12期
基金：
中国国家自然科学基金; 高等学校博士学科点专项科研基金;
关键词：
DSCAM-AS1; endocrine therapy; long noncoding RNA; luminal breast cancer; prognostic factor; LONG NONCODING RNAS;
D O I：
10.1002/cam4.1603
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
DSCAM-AS1 is one of the few intensively studied lncRNAs with high specific expression in luminal breast cancer. It is directly regulated by estrogen receptor alpha (ER alpha) and plays vital roles in tumor proliferation, invasion, and tamoxifen resistance. However, the detailed function of DSCAM-AS1 in tumor progression and its clinical significance remain unclear. We reveal that DSCAM-AS1 regulates cell proliferation and colony formation by inducing the G1/S transition. RNA-seq analysis demonstrated that DSCAM-AS1 participates in crucial biological processes, including DNA replication, the G1/S phase transition, sister chromatid cohesion, chromosome segregation, protein localization to the chromosome and DNA recombination. Most importantly, in the retrospectively registered clinical analysis, high expression of DSCAM-AS1 is a poor prognostic factor in patients with luminal breast cancer treated with endocrine therapy. In conclusion, DSCAM-AS1 is a promising clinical therapeutic target that may prolong survival of luminal breast cancer patients treated with endocrine therapy.
引用
收藏
页码：6137 / 6146
页数：10
相关论文
共 19 条
  • [11] Dysregulated miR-183 inhibits migration in breast cancer cells
    Lowery, Aoife J.
    Miller, Nicola
    Dwyer, Roisin M.
    Kerin, Michael J.
    [J]. BMC CANCER, 2010, 10
  • [12] Long non-coding RNAs: insights into functions
    Mercer, Tim R.
    Dinger, Marcel E.
    Mattick, John S.
    [J]. NATURE REVIEWS GENETICS, 2009, 10 (03) : 155 - 159
  • [13] Luminal long non-coding RNAs regulated by estrogen receptor alpha in a ligand-independent manner show functional roles in breast cancer
    Miano, Valentina
    Ferrero, Giulio
    Reineri, Stefania
    Caizzi, Livia
    Annaratone, Laura
    Ricci, Laura
    Cutrupi, Santina
    Castellano, Isabella
    Cordero, Francesca
    De Bortoli, Michele
    [J]. ONCOTARGET, 2016, 7 (03) : 3201 - 3216
  • [14] The miR-99 family regulates the DNA damage response through its target SNF2H
    Mueller, A. C.
    Sun, D.
    Dutta, A.
    [J]. ONCOGENE, 2013, 32 (09) : 1164 - 1172
  • [15] The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression
    Niknafs, Yashar S.
    Han, Sumin
    Ma, Teng
    Speers, Corey
    Zhang, Chao
    Wilder-Romans, Kari
    Iyer, Matthew K.
    Pitchiaya, Sethuramasundaram
    Malik, Rohit
    Hosono, Yasuyuki
    Prensner, John R.
    Poliakov, Anton
    Singhal, Udit
    Xiao, Lanbo
    Kregel, Steven
    Siebenaler, Ronald F.
    Zhao, Shuang G.
    Uhl, Michael
    Gawronski, Alexander
    Hayes, Daniel F.
    Pierce, Lori J.
    Cao, Xuhong
    Collins, Colin
    Backofen, Rolf
    Sahinalp, Cenk S.
    Rae, James M.
    Chinnaiyan, Arul M.
    Feng, Felix Y.
    [J]. NATURE COMMUNICATIONS, 2016, 7
  • [16] Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
    Parker, Joel S.
    Mullins, Michael
    Cheang, Maggie C. U.
    Leung, Samuel
    Voduc, David
    Vickery, Tammi
    Davies, Sherri
    Fauron, Christiane
    He, Xiaping
    Hu, Zhiyuan
    Quackenbush, John F.
    Stijleman, Inge J.
    Palazzo, Juan
    Marron, J. S.
    Nobel, Andrew B.
    Mardis, Elaine
    Nielsen, Torsten O.
    Ellis, Matthew J.
    Perou, Charles M.
    Bernard, Philip S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (08) : 1160 - 1167
  • [17] MicroRNA miR-183 Functions as an Oncogene by Targeting the Transcription Factor EGR1 and Promoting Tumor Cell Migration
    Sarver, Aaron L.
    Li, Lihua
    Subramanian, Subbaya
    [J]. CANCER RESEARCH, 2010, 70 (23) : 9570 - 9580
  • [18] miR-382 inhibits migration and invasion by targeting ROR1 through regulating EMT in ovarian cancer
    Tan, Hong
    He, Qingnan
    Gong, Guanhui
    Wang, Yixuan
    Li, Juanni
    Wang, Junpu
    Zhu, Ding
    Wu, Xiaoying
    [J]. INTERNATIONAL JOURNAL OF ONCOLOGY, 2016, 48 (01) : 181 - 190
  • [19] IncRNA Directs Cooperative Epigenetic Regulation Downstream of Chemokine Signals
    Xing, Zhen
    Lin, Aifu
    Li, Chunlai
    Liang, Ke
    Wang, Shouyu
    Liu, Yang
    Park, Peter K.
    Qin, Li
    Wei, Yongkun
    Hawke, David H.
    Hung, Mien-Chie
    Lin, Chunru
    Yang, Liuqing
    [J]. CELL, 2014, 159 (05) : 1110 - 1125
12